Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KA

Kineta (KA) Stock Price, News & Analysis

Kineta logo

About Kineta Stock (NASDAQ:KA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.57
$0.86
52-Week Range
N/A
Volume
530,700 shs
Average Volume
409,478 shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Receive KA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter.

KA Stock News Headlines

Kineta and TuHURA Enter Acquisition Agreement
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Kineta, Inc Transitioning from Nasdaq to OTC Markets
See More Headlines

KA Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Kineta investors own include Intel (INTC), Motley Fool 100 Index ETF (TMFC), Argan (AGX), AST SpaceMobile (ASTS), AutoZone (AZO), Cadence Design Systems (CDNS) and Walt Disney (DIS).

Company Calendar

Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KA
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.10 million
Pretax Margin
-345.77%

Debt

Sales & Book Value

Annual Sales
$5.44 million
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
N/A

Miscellaneous

Free Float
9,350,000
Market Cap
$7.04 million
Optionable
Not Optionable
Beta
0.46
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:KA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners